Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma
Martin H. Voss(Memorial Sloan Kettering Cancer Center), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Devyn Taylor Coskey(Memorial Sloan Kettering Cancer Center), Ana M. Molina(Cornell University), Victor E. Reuter(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), Chung‐Han Lee(Memorial Sloan Kettering Cancer Center), James J. Hsieh(Memorial Sloan Kettering Cancer Center), Satish K. Tickoo(Unknown), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Joshua Chaim(Cornell University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Patricia Wang(Cornell University), Sujata Patil(Kettering University), William Lee(Drexel University), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Kaitlin M. Woo(Cornell University), S. Duygu Selçuklu(Memorial Sloan Kettering Cancer Center)
Cited by 85
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k